Jane H. Hsiao Ph.D., MBA
Net Worth

Last updated:

What is Jane H. Hsiao Ph.D., MBA net worth?

The estimated net worth of Dr. Jane H. Hsiao Ph.D., MBA is at least $50,556,638 as of 17 Jan 2024. He owns shares worth $37,799,838 as insider and has received compensation worth at least $12,756,800 in OPKO Health, Inc..

What is the salary of Jane H. Hsiao Ph.D., MBA?

Dr. Jane H. Hsiao Ph.D., MBA salary is $911,200 per year as Vice Chairman & Chief Technical Officer in OPKO Health, Inc..

How old is Jane H. Hsiao Ph.D., MBA?

Dr. Jane H. Hsiao Ph.D., MBA is 78 years old, born in 1947.

What stocks does Jane H. Hsiao Ph.D., MBA currently own?

As insider, Dr. Jane H. Hsiao Ph.D., MBA owns shares in one company:

Company Title Shares Price per share Total value
OPKO Health, Inc. (OPK) Vice Chairman & Chief Technical Officer 27,999,880 $1.35 $37,799,838

What does OPKO Health, Inc. do?

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK logo
OPK
OPKO Health, Inc.
$1.35

Jane H. Hsiao Ph.D., MBA insider trading

OPKO Health, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 150,000 $0.95 $142,500
Purchase
Common Stock 150,010 $0.87 $130,959
Purchase
Common Stock 34,058 $1.26 $42,913
Purchase
Common Stock 65,942 $1.27 $83,746
Purchase
Common Stock 10 $3.73 $37
Purchase
Common Stock 400,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 40,000 $3.47 $138,600
Purchase
Common Stock 80,000 $6.98 $558,080
Option
Stock Option (Right to Buy) 112,500 $7.61 $856,125
Option
Common Stock 112,500 $7.61 $856,125
Purchase
Common Stock 1,200 $10.65 $12,774
Purchase
Common Stock 1,200 $9.99 $11,988
Purchase
Common Stock 1,200 $10 $12,000
Purchase
Common Stock 1,200 $10.12 $12,142
Purchase
Common Stock 1,200 N/A N/A
Purchase
Common Stock 1,200 $9.82 $11,778
Purchase
Common Stock 1,200 $9.99 $11,988
Purchase
Common Stock 1,200 $9.99 $11,988
Purchase
Common Stock 20,000 $10.82 $216,460
Option
Common Stock 200,000 $7.99 $1,598,000
Option
Stock Option (Right to Buy) 200,000 $7.99 $1,598,000
Option
Common Stock 7,732,738 $0.63 $4,848,427
Option
Warrant (Right to Buy) 978,860 $0.67 $658,773
Option
Warrant (Right to Buy) 201,613 $2.48 $500,000
Option
Common Stock 201,613 $2.48 $500,000
Option
Common Stock 309,583 $5.23 $1,619,119
Option
Stock Option (Right to Buy) 152,304 $6.19 $942,762
Purchase
Common Stock 10,000 $8.03 $80,300
Purchase
Common Stock 10,000 $7.96 $79,600
Purchase
Common Stock 10,000 $8.17 $81,730
Purchase
Common Stock 10,000 $8.2 $81,950
Option
Common Stock 1,537,500 N/A N/A
Option
Stock Option (Right to Buy) 987,500 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Option
Common Stock 806,450 N/A N/A
Option
Series D Cumulative Convertible Preferred Stock 80,645 N/A N/A
Purchase
Common Stock 10,000 $4.33 $43,340
Purchase
Common Stock 30,000 $4.35 $130,500
Purchase
Common Stock 20,000 $4.3 $86,000
Purchase
Common Stock 10,000 $4.71 $47,110
Purchase
Common Stock 2,400,000 $3.6 $8,640,000

OPKO Health key executives

OPKO Health, Inc. executives and other stock owners filed with the SEC: